ELISA/assay

Human ubiquitin-like modifier, ISG15 ELISA Kit

MBS700182

48-Strip-Wells

590 USD

ELISA Kit

Human ubiquitin-like modifier, ISG15 ELISA Kit

ISG15 ubiquitin-like modifier

Human ubiquitin-like modifier (ISG15) ELISA kit; G1P2; IFI15; UCRP; interferon; alpha-inducible protein (clone IFI-15K) ; interferon-induced 17-kDa/15-kDa protein; interferon-stimulated protein; 15 kDa; ubiquitin cross-reactive protein; ISG15 ubiquitin-like modifier

ubiquitin-like protein ISG15; Ubiquitin-like protein ISG15; ubiquitin-like protein ISG15; ubiquitin cross-reactive protein; interferon-stimulated protein, 15 kDa; interferon-induced 17-kDa/15-kDa protein; interferon, alpha-inducible protein (clone IFI-15K); ISG15 ubiquitin-like modifier; Interferon-induced 15 kDa protein; Interferon-induced 17 kDa protein; IP17; Ubiquitin cross-reactive protein; hUCRP

ISG15

ISG15; ISG15; G1P2; IP17; UCRP; IFI15; hUCRP; G1P2; UCRP; IP17; hUCRP

ISG15_HUMAN

Human

165

This assay has high sensitivity and excellent specificity for detection of human ISG15. No significant cross-reactivity or interference between human ISG15 and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, tissue homogenates, cell culture supernates. Assay Type: Sandwich. Detection Range: 0.78 ng/ml-50 ng/ml. Sensitivity: The minimum detectable dose of human ISG15 is typically less than 0.195 ng/ml.The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration that could be differentiated from zero. It was determined the mean O.D value of 20 replicates of the zero standard added by their three standard deviations.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV%<8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision: Inter-assay Precision (Precision between assays): CV%<10%. Three samples of known concentration were tested in twenty assays to assess.

Principle of the Assay: This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for ISG15 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any ISG15 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for ISG15 is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of ISG15 bound in the initial step. The color development is stopped and the intensity of the color is measured.

4826774

NP_005092.1

NM_005101.3

P05161

17,888 Da

Antiviral Mechanism By IFN-stimulated Genes Pathway (530760); Cytokine Signaling In Immune System Pathway (366171); ISG15 Antiviral Mechanism Pathway (530761); Immune System Pathway (106386); Innate Immune System Pathway (106387); Interferon Signaling Pathway (187103); Interferon Alpha/beta Signaling Pathway (187104); Negative Regulators Of RIG-I/MDA5 Signaling Pathway (187102); RIG-I-like Receptor Signaling Pathway (117292); RIG-I-like Receptor Signaling Pathway (116128)

The protein encoded by this gene is a ubiquitin-like protein that is conjugated to intracellular target proteins upon activation by interferon-alpha and interferon-beta. Several functions have been ascribed to the encoded protein, including chemotactic activity towards neutrophils, direction of ligated target proteins to intermediate filaments, cell-to-cell signaling, and antiviral activity during viral infections. While conjugates of this protein have been found to be noncovalently attached to intermediate filaments, this protein is sometimes secreted. [provided by RefSeq, Dec 2012]

Function: Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation-inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA-induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity.19 PublicationsManual assertion based on experiment in:Ref.11

48-Strip-Wells

590 USD

96-Strip-Wells

850

5x96-Strip-Wells

2880

10x96-Strip-Wells

5440